Natural health product · NPN 80120191
Abreva
Yes: licensed in Canada
The product licence is active. Whether the product is actually on the market is a separate, voluntary notice; the official record shows it.
Licence status Active; licensed July 29, 2022; licence last revised August 29, 2022.
- Natural Product Number (NPN)
- 80120191
- Licence holder
- Haleon Canada ULCMississauga, Ontario, Canada
- Dosage form
- Cream
- Route
- Topical
- Licensing route
- General (non-traditional)
- First licensed
- July 29, 2022
- Licence last revised
- August 29, 2022
Medicinal ingredients
Per dosage unit, as licensed.
| Ingredient | Amount | Source and potency |
|---|---|---|
| 1-Docosanol | 10 % (w/w) |
What it is licensed for
The licence’s own wording. Directions, doses, cautions and warnings are on the official record and the label.
- Cold Sore Treatment. For the treatment of acute episodes of recurrent oral-facial herpes simplex (fever blisters or cold sores) in adults. Treats cold sores / fever blisters on the lips and face. For the treatment of recurrent cold sores. Abreva is clinically proven to shorten the healing time (duration) of your cold sore. Shortens healing time and the duration of cold sore symptoms including pain, burning, tingling and itching. Reduces the duration of pain, burning, itching and tingling associated with cold sores. Clinically proven to speed cold sore healing. In clinical trials, the time to complete healing was statistically significantly shorter in the Abreva group (4.1 days) than the placebo group (4.8 days). ABREVA demonstrated statistically significant reductions in duration of the oral-facial herpes simplex associated symptoms of pain and/or burning, itching or tingling when compared to placebo. The predominant mechanism for the anti-HSV activity of docosanol appears to be inhibition of fusion between the plasma membrane and the HSV envelope, which helps to treat cold sores. Blocks viral entry into the cell and subsequent viral replication, thereby helping to treat cold sores. Viral Entry Blocking Agent to help treat cold sores. Inhibits entry of the cold sore virus into surrounding cells to help treat cold sores. ABREVA contains docosanol, a substance which blocks the ability of the cold sore virus to enter your skin cells, limiting its ability to spread to surrounding cells and thereby helping to treat cold sores. Abreva soothes cold sores on contact.
Non-medicinal ingredients
Light mineral oil; Sucrose stearate; alpha-D-Glucopyranoside, beta-D-Fructofuranosyl, Dioctadecanoate; Propylene glycol; Water; Benzyl alcohol